New York Assembly Bill A02126

New York 2025-2026 Regular Session

• Introduced: 1/15/25
• Refer: 1/15/25
• Refer: 1/7/26

Caption

Establishes a pilot program on the referenced rate for prescription drugs; relates to reducing the cost of prescription drugs by establishing maximum wholesale drug prices that are the same as the prices in Canada.

Impact

If enacted, A02126 would create a framework for regulating the prices of prescription drugs within the state, aligning them with lower prices seen in Canada. This legislation has the potential to affect various stakeholders in the pharmaceutical industry, including manufacturers, wholesalers, and retailers, as they would need to adjust their pricing structures to comply with the new law. Furthermore, it could pave the way for similar regulatory measures aimed at overall health care cost reduction within the state, possibly influencing how other states approach drug pricing reforms.

Summary

Bill A02126 seeks to establish a pilot program aimed at reducing the cost of prescription drugs by implementing maximum wholesale drug prices equivalent to those in Canada. The bill's intent is to address rising prescription drug costs, which have become a pressing issue for many residents seeking affordable healthcare solutions. By adopting price controls based on the Canadian model, proponents of the bill argue that it could lead to significant savings for consumers and ultimately promote better health outcomes due to increased access to necessary medications.

Contention

The proposal has sparked discussions regarding the balance between cost control and the potential implications for drug supply and innovation. Opponents of the bill argue that capping prices could disincentivize pharmaceutical companies from investing in new drug development, ultimately leading to fewer innovations in treatments and therapies. Proponents, however, contend that the benefits of making drugs more affordable to consumers outweigh these concerns, asserting that the current pricing models are unsustainable and that change is necessary to ensure government accountability to public health needs.